Toxicity of chloroquine and hydroxychloroquine following therapeutic use or overdose

References

• Rainsford KD, Parke AL, Clifford-Rashotte M, et al. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology. 2015;23(5):231–269.
   PubMed Web of Science ®Google Scholar
• Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020;71(15):732–739.
   Web of Science ®Google Scholar
• Commissioner of the Emergency Use Authorization. FDA. 2020. [cited 2020 Jun 17]; Available from: https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization.
   Google Scholar
• Goodman JL, Borio L. Finding effective treatments for COVID-19: scientific integrity and public confidence in a time of crisis. JAMA. 2020;323(19):1899.
   PubMed Web of Science ®Google Scholar
• Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious diseases society of America guidelines on the treatment and management of patients with COVID-19. Clin Infect Dis. 2020. DOI:10.1093/cid/ciaa1063. Online ahead of print.
   Google Scholar
• Information on COVID-19 treatment, prevention and research. COVID-19 treatment guidelines. [cited 2020 Jun 17]. Available from: https://www.covid19treatmentguidelines.nih.gov/.
   Google Scholar
• Lalloo DG, Shingadia D, Bell DJ, et al. UK malaria treatment guidelines 2016. J Infect. 2016;72(6):635–649.
   PubMed Web of Science ®Google Scholar
• Hernandez AV, Roman YM, Pasupuleti V, et al. Hydroxychloroquine or chloroquine for treatment or prophylaxis of COVID-19: a living systematic review. Ann Intern Med. 2020;173(4):287–296.
   Web of Science ®Google Scholar
• Chen Z, Hu J, Zhang Z, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. Epidemiology; 2020; [cited 2020 Jun 17]. Available from: https://www.medrxiv.org/content/10.1101/2020.03.22.20040758v3
   Google Scholar
• Borba MGS, Val FFA, Sampaio VS, et al. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. JAMA Netw Open. 2020;3(4):e208857
   PubMed Web of Science ®Google Scholar
• Ursing J, Kofoed P-E, Rodrigues A, et al. Chloroquine is grossly overdosed and overused but well tolerated in Guinea-bissau. Antimicrob Agents Chemother. 2009;53(1):180–185.
   PubMed Web of Science ®Google Scholar
• Croft AM, Clayton TC, World MJ. Side effects of mefloquine prophylaxis for malaria: an independent randomized controlled trial. Trans R Soc Trop Med Hyg. 1997;91(2):199–203.
   PubMed Web of Science ®Google Scholar
• Jacquerioz FA, Croft AM. Drugs for preventing malaria in travellers. Cochrane Database Syst Rev. 2009;(4):CD006491.
   PubMed Web of Science ®Google Scholar
• Covid-19 living Data [Internet]. [cited 2020 Jun 17]. Available from: https://covid-nma.com/.
   Google Scholar
• Boulware DR, Pullen MF, Bangdiwala AS, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med. 2020;383(6):517–525.
   PubMed Web of Science ®Google Scholar
• Nagaraja BS, Ramesh KN, Dhar D, et al. HyPE study: hydroxychloroquine prophylaxis-related adverse events’ analysis among healthcare workers during COVID-19 pandemic: a rising public health concern. J Public Health (Oxf). 2020;42(3):493–503.
   Google Scholar
• Huang M, Tang T, Pang P, et al. Treating COVID-19 with chloroquine. J Mol Cell Biol. 2020;12(4):322–325.
   PubMed Web of Science ®Google Scholar
• Zachariah P, Johnson CL, Halabi KC, et al. Epidemiology, clinical features, and disease severity in patients with coronavirus disease 2019 (COVID-19) in a Children’s Hospital in New York City, New York. JAMA Pediatr. 2020;e202430. DOI:10.1001/jamapediatrics.2020.2430. Online ahead of print.
   PubMed Web of Science ®Google Scholar
• Munster T, Gibbs JP, Shen D, et al. Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. Arthritis Rheum. 2002;46(6):1460–1469.
   PubMed Web of Science ®Google Scholar
• Croft AM, Whitehouse DP, Cook GC, et al. Safety evaluation of the drugs available to prevent malaria. Expert Opin Drug Saf. 2002;1(1):19–27.
   PubMedGoogle Scholar
• Gevers S, Kwa MSG, Wijnans E, et al. Safety considerations for chloroquine and hydroxychloroquine in the treatment of COVID-19. Clin Microbiol Infect. 2020;26(9):1276–1277.
   PubMed Web of Science ®Google Scholar
• Makin AJ, Wendon J, Fitt S, et al. Fulminant hepatic failure secondary to hydroxychloroquine. Gut. 1994;35(4):569–570.
   PubMed Web of Science ®Google Scholar
• Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020;369:m1849.
   PubMed Web of Science ®Google Scholar
• Rosenberg ES, Dufort EM, Udo T, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. JAMA. 2020;323(24):2493.
   PubMed Web of Science ®Google Scholar
• Gautret P, Lagier J-C, Parola P, et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study. Travel Med Infect Dis. 2020;34:101663.
   PubMed Web of Science ®Google Scholar
• Million M, Lagier J-C, Gautret P, et al. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: a retrospective analysis of 1061 cases in Marseille, France. Travel Med Infect Dis. 2020;35:101738.
   PubMed Web of Science ®Google Scholar
• Falcão MB, Pamplona de Góes Cavalcanti L, Filgueiras Filho NM, et al. Case report: hepatotoxicity associated with the use of hydroxychloroquine in a patient with COVID-19. Am J Trop Med Hyg. 2020;102(6):1214–1216.
   PubMed Web of Science ®Google Scholar
• Cansu DU, Korkmaz C. Hypoglycaemia induced by hydroxychloroquine in a non-diabetic patient treated for RA. Rheumatol Oxf Engl. 2007;47(3):378–379.
   Web of Science ®Google Scholar
• Riou B, Barriot P, Rimailho A, et al. Treatment of severe chloroquine poisoning. N Engl J Med. 1988;318(1):1–6.
   PubMed Web of Science ®Google Scholar
• Shojania K, Koehler BE, Elliott T. Hypoglycemia induced by hydroxychloroquine in a type II diabetic treated for polyarthritis. J Rheumatol. 1999;26:195–196.
   PubMed Web of Science ®Google Scholar
• Baretić M. Case report of chloroquine therapy and hypoglycaemia in type 1 diabetes: What should we have in mind during the COVID-19 pandemic? Diabetes Metab Syndr. 2020;14(4):355–356.
   PubMed Web of Science ®Google Scholar
• Unübol M, Ayhan M, Guney E. Hypoglycemia induced by hydroxychloroquine in a patient treated for rheumatoid arthritis. J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis. 2011;17:46–47.
   Google Scholar
• Infante M, Ricordi C, Fabbri A. Antihyperglycemic properties of hydroxychloroquine in patients with diabetes: risks and benefits at the time of COVID-19 pandemic. J Diabetes. 2020;12(9):659–667.
   PubMed Web of Science ®Google Scholar
• White NJ. Cardiotoxicity of antimalarial drugs. Lancet Infect Dis. 2007;7(8):549–558.
   PubMed Web of Science ®Google Scholar
• Chatre C, Roubille F, Vernhet H, et al. Cardiac complications attributed to chloroquine and hydroxychloroquine: a systematic review of the literature. Drug Saf. 2018;41(10):919–931.
   PubMed Web of Science ®Google Scholar
• Abu-Aisha H, Abu-Sabaa HM, Nur T. Cardiac arrest after intravenous chloroquine injection. J Trop Med Hyg. 1979;82(2):36–37.
   PubMed Web of Science ®Google Scholar
• Scott V. Single intravenous injections of chloroquine in the treatment of falciparum malaria: toxic and immediate therapeutic effects in 110 cases. Am J Trop Med Hyg. 1950;30(4):503–510.
   PubMed Web of Science ®Google Scholar
• Abiose AK, Grossmann M, Tangphao O, et al. Chloroquine-induced venodilation in human hand veins. Clin Pharmacol Ther. 1997;61(6):677–683.
   PubMed Web of Science ®Google Scholar
• Ghigo D, Aldieri E, Todde R, et al. Chloroquine stimulates nitric oxide synthesis in murine, porcine, and human endothelial cells. J Clin Invest. 1998;102(3):595–605.
   PubMed Web of Science ®Google Scholar
• Haeusler IL, Chan XHS, Guérin PJ, et al. The arrhythmogenic cardiotoxicity of the quinoline and structurally related antimalarial drugs: a systematic review. BMC Med. 2018;16(1):200
   PubMed Web of Science ®Google Scholar
• Sánchez-Chapula JA, Salinas-Stefanon E, Torres-Jácome J, et al. Blockade of currents by the antimalarial drug chloroquine in feline ventricular myocytes. J Pharmacol Exp Ther. 2001;297(1):437–445.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Menchaca AA, Navarro-Polanco RA, Ferrer-Villada T, et al. The molecular basis of chloroquine block of the inward rectifier Kir2.1 channel. Proc Natl Acad Sci USA. 2008;105(4):1364–1368.
   PubMed Web of Science ®Google Scholar
• Mzayek F, Deng H, Mather FJ, et al. Randomized dose-ranging controlled trial of AQ-13, a candidate antimalarial, and chloroquine in healthy volunteers. PLoS Clin Trial. 2007;2(1):e6.
   PubMedGoogle Scholar
• Morgan ND, Patel SV, Dvorkina O. Suspected hydroxychloroquine-associated QT-interval prolongation in a patient with systemic lupus erythematosus. J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis. 2013;19:286–288.
   Google Scholar
• Yogasundaram H, Putko BN, Tien J, et al. Hydroxychloroquine-induced cardiomyopathy: case report, pathophysiology, diagnosis, and treatment. Can J Cardiol. 2014;30(12):1706–1715.
   PubMed Web of Science ®Google Scholar
• [cited 2020. Jun 17]. Available from: https://www.who.int/malaria/mpac/mpac-mar2017-erg-cardiotoxicity-report-session2.pdf.
   Google Scholar
• Molina JM, Delaugerre C, Le Goff J, et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med Mal Infect. 2020;50(4):384.
   PubMed Web of Science ®Google Scholar
• Perinel S, Launay M, Botelho-Nevers É, et al. Towards optimization of hydroxychloroquine dosing in intensive care unit COVID-19 patients. Clin Infect Dis. 2020. DOI:10.1093/cid/ciaa394. Online ahead of print..
   PubMed Web of Science ®Google Scholar
• Saleh M, Gabriels J, Chang D, et al. Effect of chloroquine, hydroxychloroquine, and azithromycin on the corrected QT interval in patients with SARS-CoV-2 infection. Circ Arrhythm Electrophysiol. 2020;13(6):e008662.
   PubMed Web of Science ®Google Scholar
• Mazzanti A, Briani M, Kukavica D, et al. Association of hydroxychloroquine with QTc interval in patients with COVID-19. Circulation. 2020;142(5):513–515.
   PubMed Web of Science ®Google Scholar
• Mahévas M, Tran V-T, Roumier M, et al. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. BMJ. 2020;369:m1844.
   PubMed Web of Science ®Google Scholar
• van den Broek MPH, Möhlmann JE, Abeln BGS, et al. Chloroquine-induced QTc prolongation in COVID-19 patients. Neth Heart J. 2020;28(7-8):406–409.
   PubMed Web of Science ®Google Scholar
• Cipriani A, Zorzi A, Ceccato D, et al. Arrhythmic profile and 24-hour QT interval variability in COVID-19 patients treated with hydroxychloroquine and azithromycin. Int J Cardiol. 2020. DOI:10.1016/j.ijcard.2020.06.005. Online ahead of print.
   Web of Science ®Google Scholar
• Hor CP, Hussin N, Nalliah S, et al. Experience of short-term hydroxychloroquine and azithromycin in COVID-19 patients and effect on QTc trend. J Infect. 2020;81(2):e117–e119.
   PubMed Web of Science ®Google Scholar
• Bessière F, Roccia H, Delinière A, et al. Assessment of QT intervals in a case series of patients with coronavirus disease 2019 (COVID-19) infection treated with hydroxychloroquine alone or in combination with azithromycin in an intensive care unit. JAMA Cardiol. 2020:e201787. DOI:10.1001/jamacardio.2020.1787. Online ahead of print.
   PubMed Web of Science ®Google Scholar
• Szekely Y, Lichter Y, Shrkihe BA, et al. Chloroquine-induced torsades de pointes in a patient with coronavirus disease 2019. Heart Rhythm. 2020;17(9):1452–1455.
   PubMed Web of Science ®Google Scholar
• Maraj I, Hummel JP, Taoutel R, et al. Incidence and determinants of QT interval prolongation in COVID-19 patients treated with hydroxychloroquine and azithromycin. J Cardiovasc Electrophysiol. 2020;31(8):1904–1907.
   PubMed Web of Science ®Google Scholar
• Chorin E, Wadhwani L, Magnani S, et al. QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin. Heart Rhythm. 2020;17(9):1425–1433.
   PubMed Web of Science ®Google Scholar
• Mercuro NJ, Yen CF, Shim DJ, et al. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020:e201834. DOI:10.1001/jamacardio.2020.1834. Online ahead of print.
   PubMed Web of Science ®Google Scholar
• Experience with Hydroxychloroquine and Azithromycin in the COVID-19 Pandemic: Implications for QT Interval Monitoring | medRxiv [Internet]. [cited 2020. Jun 17]. Available from: https://www.medrxiv.org/content/10.1101/2020.04.22.20075671v1.
   Google Scholar
• Sharma AN, Mesinkovska NA, Paravar T. Characterizing the adverse dermatologic effects of hydroxychloroquine: a systematic review. J Am Acad Dermatol. 2020;83(2):563–578.
   Web of Science ®Google Scholar
• Phillips-Howard PA, Warwick Buckler J. Idiosyncratic reaction resembling toxic epidermal necrolysis caused by chloroquine and maloprim. Br Med J (Clin Res Ed)). 1988;296(6636):1605.
   PubMed Web of Science ®Google Scholar
• Boffa MJ, Chalmers RJ. Toxic epidermal necrolysis due to chloroquine phosphate. Br J Dermatol. 1994;131(3):444–445.
   PubMed Web of Science ®Google Scholar
• Kanwar AJ, Singh OP. Toxic epidermal necrolysis-drug induced (report of 2 cases). Indian J Dermatol. 1976;21(4):73–77.
   PubMedGoogle Scholar
• Barailler H, Milpied B, Chauvel A, et al. Delayed hypersensitivity skin reaction to hydroxychloroquine: successful short desensitization. J Allergy Clin Immunol Pract. 2019;7(1):307–308.
   PubMed Web of Science ®Google Scholar
• Mates M, Zevin S, Breuer GS, et al. Desensitization to hydroxychloroquine–experience of 4 patients. J Rheumatol. 2006;33(4):814–816.
   PubMed Web of Science ®Google Scholar
• Litaiem N, Hajlaoui K, Karray M, et al. Acute generalized exanthematous pustulosis after COVID-19 treatment with hydroxychloroquine. Dermatol Ther. 2020;e13565. DOI:10.1111/dth.13565. Online ahead of print.
   PubMed Web of Science ®Google Scholar
• Robustelli Test E, Vezzoli P, Carugno A, et al. Acute generalized exanthematous pustulosis with erythema multiforme-like lesions in a COVID-19 woman. J Eur Acad Dermatol Venereol. 2020. DOI:10.1111/jdv.16613. Online ahead of print.
   Google Scholar
• Grandolfo M, Romita P, Bonamonte D, et al. Drug reaction with eosinophilia and systemic symptoms syndrome to hydroxychloroquine, an old drug in the spotlight in the COVID-19 era. Dermatol Ther. 2020;:e13499. DOI:10.1111/dth.13499. Online ahead of print.
   PubMed Web of Science ®Google Scholar
• Kutlu Ö, Metin A. A case of exacerbation of psoriasis after oseltamivir and hydroxychloroquine in a patient with COVID-19: will cases of psoriasis increase after COVID-19 pandemic? Dermatol Ther. 2020;e13383. DOI:10.1111/dth.13383. Online ahead of print.
   PubMed Web of Science ®Google Scholar
• Schwartz RA, Janniger CK. Generalized pustular figurate erythema: a newly delineated severe cutaneous drug reaction linked with hydroxychloroquine. Dermatol Ther. 2020;33(3):e13380.
   PubMed Web of Science ®Google Scholar
• Herrero-Moyano M, Capusan TM, Andreu-Barasoain M, et al. A clinicopathological study of 8 patients with COVID-19 pneumonia and a late-onset exanthema. J Eur Acad Dermatol Venereol. 2020. DOI:10.1111/jdv.16631. Online ahead of print.
   PubMed Web of Science ®Google Scholar
• Sato K, Mano T, Iwata A, et al. Neuropsychiatric adverse events of chloroquine: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database. Biosci Trends. 2020;14(2):139–143.
   PubMed Web of Science ®Google Scholar
• Collins KP, Jackson KM, Gustafson DL. Hydroxychloroquine: a physiologically-based pharmacokinetic model in the context of cancer-related autophagy modulation. J Pharmacol Exp Ther. 2018;365(3):447–459.
   PubMed Web of Science ®Google Scholar
• Garg P, Mody P, Lall KB. Toxic psychosis due to chloroquine-not uncommon in children. Clin Pediatr (Phila)). 1990;29(8):448–450.
   PubMed Web of Science ®Google Scholar
• Rab SM. Two cases of chloroquine psychosis. Br Med J. 1963;1(5340):1275.
   PubMed Web of Science ®Google Scholar
• Mustakallio KK, Putkonen T, Pihkanen TA. Chloroquine psychosis?. Lancet Lond Engl. 1962;280(7270):1387–1388.
   Google Scholar
• Biswas PS, Sen D, Majumdar R. Psychosis following chloroquine ingestion: a 10-year comparative study from a malaria-hyperendemic district of India. Gen Hosp Psychiatry. 2014;36(2):181–186.
   PubMed Web of Science ®Google Scholar
• Bogaczewicz A, Sobów T. Psychiatric adverse effects of chloroquine. Psychiatr Psychol Klin. 2017;17(2):111–114.
   Web of Science ®Google Scholar
• Thompson AJ, Lummis SCR. Antimalarial drugs inhibit human 5-HT(3) and GABA(A) but not GABA(C) receptors. Br J Pharmacol. 2008;153(8):1686–1696.
   PubMed Web of Science ®Google Scholar
• 006002s044lbl.pdf [Internet]. [cited 2020. Jun 17]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/006002s044lbl.pdf.
   Google Scholar
• 009768s037s045s047lbl.pdf [Internet]. [cited 2020. Jun 17]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/009768s037s045s047lbl.pdf.
   Google Scholar
• Nkhoma ET, Poole C, Vannappagari V, et al. The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis. Blood Cells Mol Dis. 2009;42(3):267–278.
   PubMed Web of Science ®Google Scholar
• Reference GH. Glucose-6-phosphate dehydrogenase deficiency. Genet. Home Ref. [cited 2020 Jun 17]. Available from: https://ghr.nlm.nih.gov/condition/glucose-6-phosphate-dehydrogenase-deficiency.
   Google Scholar
• Mohammad S, Clowse MEB, Eudy AM, et al. Examination of hydroxychloroquine use and hemolytic anemia in G6PDH-deficient patients. Arthritis Care Res (Hoboken). 2018;70(3):481–485.
   PubMed Web of Science ®Google Scholar
• Maillart E, Leemans S, Van Noten H, et al. A case report of serious haemolysis in a glucose-6-phosphate dehydrogenase-deficient COVID-19 patient receiving hydroxychloroquine. Infect Dis (Lond). 2020;52(9):659–661.
   Google Scholar
• Kuipers MT, Zwieten R, Heijmans J, et al. G6PD deficiency-associated hemolysis and methemoglobinemia in a COVID-19 patient treated with chloroquine. Am J Hematol. 2020;95(8):E194–E196.
   PubMed Web of Science ®Google Scholar
• Beauverd Y, Adam Y, Assouline B, et al. COVID-19 infection and treatment with hydroxychloroquine cause severe haemolysis crisis in a patient with glucose-6-phosphate dehydrogenase deficiency. Eur J Haematol. 2020;105(3):357–359.
   PubMed Web of Science ®Google Scholar
• Jorge A, Ung C, Young LH, et al. Hydroxychloroquine retinopathy - implications of research advances for rheumatology care. Nat Rev Rheumatol. 2018;14(12):693–703.
   PubMed Web of Science ®Google Scholar
• Tobin DR, Krohel G, Rynes RI. Hydroxychloroquine. Seven-year experience. Arch Ophthalmol. 1982;100(1):81–83.
   PubMedGoogle Scholar
• Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 2014;132(12):1453–1460.
   PubMed Web of Science ®Google Scholar
• Browning DJ, Lee C. Somatotype, the risk of hydroxychloroquine retinopathy, and safe daily dosing guidelines. Clin Ophthalmol. 2018;12:811–818.
   PubMed Web of Science ®Google Scholar
• Elman A, Gullberg R, Nilsson E, et al. Chloroquine retinopathy in patients with rheumatoid arthritis. Scand J Rheumatol. 1976;5(3):161–166.
   PubMed Web of Science ®Google Scholar
• Bergholz R, Schroeter J, Rüther K. Evaluation of risk factors for retinal damage due to chloroquine and hydroxychloroquine. Br J Ophthalmol. 2010;94(12):1637–1642.
   PubMed Web of Science ®Google Scholar
• Wolfe F, Marmor MF. Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2010;62(6):775–784.
   PubMed Web of Science ®Google Scholar
• Marmor MF, Kellner U, Lai TYY, American Academy of Ophthalmology, et al. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 Revision). Ophthalmology. 2016;123(6):1386–1394.
   PubMed Web of Science ®Google Scholar
• Leung L-SB, Neal JW, Wakelee HA, et al. Rapid onset of retinal toxicity from high-dose hydroxychloroquine given for cancer therapy. Am J Ophthalmol. 2015;160(4):799–805.e1.
   PubMed Web of Science ®Google Scholar
• Browning DJ. Hydroxychloroquine and chloroquine retinopathy: screening for drug toxicity. Am J Ophthalmol. 2002;133(5):649–656.
   PubMed Web of Science ®Google Scholar
• Nika M, Blachley TS, Edwards P, et al. Regular examinations for toxic maculopathy in long-term chloroquine or hydroxychloroquine users. JAMA Ophthalmol. 2014;132(10):1199–1208.
   PubMed Web of Science ®Google Scholar
• Marmor MF, Hu J. Effect of disease stage on progression of hydroxychloroquine retinopathy. JAMA Ophthalmol. 2014;132(9):1105–1112.
   PubMed Web of Science ®Google Scholar
• Mititelu M, Wong BJ, Brenner M, et al. Progression of hydroxychloroquine toxic effects after drug therapy cessation: new evidence from multimodal imaging. JAMA Ophthalmol. 2013;131(9):1187–1197.
   PubMed Web of Science ®Google Scholar
• Inoue S, Hasegawa K, Ito S, et al. Antimelanoma activity of chloroquine, an antimalarial agent with high affinity for melanin. Pigment Cell Res. 1993;6(5):354–358.
   PubMedGoogle Scholar
• Grassmann F, Bergholz R, Mändl J, et al. Common synonymous variants in ABCA4 are protective for chloroquine induced maculopathy (toxic maculopathy). BMC Ophthalmol. 2015;15:18.
   PubMed Web of Science ®Google Scholar
• McGhie TK, Harvey P, Su J, et al. Electrocardiogram abnormalities related to anti-malarials in systemic lupus erythematosus. Clin Exp Rheumatol. 2018;36(4):545–551.
   PubMed Web of Science ®Google Scholar
• Costedoat-Chalumeau N, Hulot J-S, Amoura Z, et al. Heart conduction disorders related to antimalarials toxicity: an analysis of electrocardiograms in 85 patients treated with hydroxychloroquine for connective tissue diseases. Rheumatology (Oxford). 2007;46(5):808–810.
   PubMed Web of Science ®Google Scholar
• Teixeira RA, Borba EF, Pedrosa A, et al. Evidence for cardiac safety and antiarrhythmic potential of chloroquine in systemic lupus erythematosus. Eur Soc Cardiol. 2014;16:887–892.
   Google Scholar
• Tönnesmann E, Kandolf R, Lewalter T. Chloroquine cardiomyopathy – a review of the literature. Immunopharmacol Immunotoxicol. 2013;35(3):434–442.
   PubMed Web of Science ®Google Scholar
• Fragasso G, Sanvito F, Baratto F, et al. Cardiotoxicity after low-dose chloroquine antimalarial therapy. Heart Vessels. 2009;24(5):385–387.
   PubMed Web of Science ®Google Scholar
• Costedoat-Chalumeau N, Hulot J-S, Amoura Z, et al. Cardiomyopathy related to antimalarial therapy with illustrative case report. Cardiology. 2007;107(2):73–80.
   PubMed Web of Science ®Google Scholar
• Richter JG, Becker A, Ostendorf B, et al. Differential diagnosis of high serum creatine kinase levels in systemic lupus erythematosus. Rheumatol Int. 2003;23(6):319–323.
   PubMed Web of Science ®Google Scholar
• Siddiqui AK, Huberfeld SI, Weidenheim KM, et al. Hydroxychloroquine-induced toxic myopathy causing respiratory failure. Chest. 2007;131(2):588–590.
   PubMed Web of Science ®Google Scholar
• Estes ML, Ewing-Wilson D, Chou SM, et al. Chloroquine neuromyotoxicity. Clinical and pathologic perspective. Am J Med. 1987;82(3):447–455.
   PubMedGoogle Scholar
• Parmar RC, Valvi CV, Kamat JR, et al. Chloroquine induced parkinsonism. J Postgrad Med. 2000;46(1):29–30.
   PubMedGoogle Scholar
• Stein M, Bell MJ, Ang LC. Hydroxychloroquine neuromyotoxicity. J Rheumatol. 2000;27(12):2927–2931.
   PubMed Web of Science ®Google Scholar
• Trinkley KE, Page RL, Lien H, et al. QT interval prolongation and the risk of torsades de pointes: essentials for clinicians. Curr Med Res Opin. 2013;29(12):1719–1726.
   PubMed Web of Science ®Google Scholar
• Staikou C, Stamelos M, Stavroulakis E. Impact of anaesthetic drugs and adjuvants on ECG markers of torsadogenicity. Br J Anaesth. 2014;112(2):217–230.
   PubMed Web of Science ®Google Scholar
• Leppert W. CYP2D6 in the metabolism of opioids for mild to moderate pain. Pharmacology. 2011;87(5-6):274–285.
   PubMed Web of Science ®Google Scholar
• McCance-Katz EF, Sullivan LE, Nallani S. Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review. Am J Addict. 2010;19(1):4–16.
   PubMed Web of Science ®Google Scholar
• Milberg P, Eckardt L, Bruns H-J, et al. Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes. J Pharmacol Exp Ther. 2002;303(1):218–225.
   PubMed Web of Science ®Google Scholar
• Fossa AA, Wisialowski T, Duncan JN, et al. Azithromycin/chloroquine combination does not increase cardiac instability despite an increase in monophasic action potential duration in the anesthetized guinea pig. Am J Trop Med Hyg. 2007;77(5):929–938.
   PubMed Web of Science ®Google Scholar
• Mehrzad R, Barza M. Weighing the adverse cardiac effects of fluoroquinolones: a risk perspective. J Clin Pharmacol. 2015;55(11):1198–1206.
   PubMed Web of Science ®Google Scholar
• Hellwig T, Gulseth M. Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation? Ann Pharmacother. 2013;47(11):1478–1487.
   PubMed Web of Science ®Google Scholar
• Rijpma SR, van den Heuvel JJMW, van der Velden M, et al. Atovaquone and quinine anti-malarials inhibit ATP binding cassette transporter activity. Malar J. 2014;13:359.
   PubMed Web of Science ®Google Scholar
• Beach SR, Celano CM, Noseworthy PA, et al. QTc prolongation, Torsades de pointes, and psychotropic medications. Psychosomatics. 2013;54(1):1–13.
   PubMed Web of Science ®Google Scholar
• Beach SR, Celano CM, Sugrue AM, et al. QT prolongation, Torsades de Pointes, and psychotropic medications: a 5-year Update. Psychosomatics. 2018;59(2):105–122.
   PubMed Web of Science ®Google Scholar
• Markowitz JS, Donovan JL, DeVane CL, et al. Effect of St John’s wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA. 2003;290(11):1500–1504.
   PubMed Web of Science ®Google Scholar
• Brüggemann RJM, Alffenaar J-WC, Blijlevens NMA, et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis. 2009;48(10):1441–1458.
   PubMed Web of Science ®Google Scholar
• Niwa T, Imagawa Y, Yamazaki H. Drug interactions between nine antifungal agents and drugs metabolized by human cytochromes P450. Curr Drug Metab. 2014;15(7):651–679.
   PubMed Web of Science ®Google Scholar
• Salem M, Reichlin T, Fasel D, et al. Torsade de pointes and systemic azole antifungal agents: analysis of global spontaneous safety reports. Glob Cardiol Sci Pract. 2017;2017(2):11. DOI:10.21542/gcsp.2017.11
   PubMedGoogle Scholar
• Devanathan AS, Anderson DJC, Cottrell ML, et al. Contemporary drug-drug interactions in HIV treatment. Clin Pharmacol Ther. 2019;105(6):1362–1377.
   PubMed Web of Science ®Google Scholar
• Fehintola FA, Akinyinka OO, Adewole IF, et al. Drug interactions in the treatment and chemoprophylaxis of malaria in HIV infected individuals in sub Saharan Africa. Curr Drug Metab. 2011;12(1):51–56.
   PubMed Web of Science ®Google Scholar
• Iwuagwu MA, Aloko KS. Adsorption of paracetamol and chloroquine phosphate by some antacids. J Pharm Pharmacol. 1992;44(8):655–658.
   PubMed Web of Science ®Google Scholar
• McElnay JC, Mukhtar HA, D'Arcy PF, et al. The effect of magnesium trisilicate and kaolin on the in vivo absorption of chloroquine. J Trop Med Hyg. 1982;85(4):159–163.
   PubMed Web of Science ®Google Scholar
• Ette EI, Brown-Awala EA, Essien EE. Chloroquine elimination in humans: effect of low-dose cimetidine. J Clin Pharmacol. 1987;27(10):813–816.
   PubMed Web of Science ®Google Scholar
• Tricco AC, Blondal E, Veroniki AA, et al. Comparative safety and effectiveness of serotonin receptor antagonists in patients undergoing chemotherapy: a systematic review and network meta-analysis. BMC Med. 2016;14(1):216.
   PubMed Web of Science ®Google Scholar
• Skinner-Adams T, Davis TM. Synergistic in vitro antimalarial activity of omeprazole and quinine. Antimicrob Agents Chemother. 1999;43(5):1304–1306.
   PubMed Web of Science ®Google Scholar
• Namazi MR. The potential negative impact of proton pump inhibitors on the immunopharmacologic effects of chloroquine and hydroxychloroquine. Lupus. 2009;18(2):104–105.
   PubMed Web of Science ®Google Scholar
• Finielz P, Gendoo Z, Chuet C, et al. Interaction between cyclosporin and chloroquine. Nephron. 1993;65(2):333.
   PubMed Web of Science ®Google Scholar
• Nampoory MR, Nessim J, Gupta RK, et al. Drug interaction of chloroquine with ciclosporin. Nephron. 1992;62(1):108–109.
   PubMed Web of Science ®Google Scholar
• Griffiths N, Lamb JF, Ogden P. The effects of chloroquine and other weak bases on the accumulation and efflux of digoxin and ouabain in HeLa cells. Br J Pharmacol. 1983;79(4):877–890.
   PubMed Web of Science ®Google Scholar
• Leden I. Digoxin-hydroxychloroquine interaction? Acta Med Scand. 1982;211(5):411–412.
   PubMedGoogle Scholar
• Goldstein LH, Gabin A, Fawaz A, et al. Azithromycin is not associated with QT prolongation in hospitalized patients with community-acquired pneumonia. Pharmacoepidemiol Drug Saf. 2015;24(10):1042–1048.
   PubMed Web of Science ®Google Scholar
• Alam K, Pahwa S, Wang X, et al. Downregulation of organic anion transporting polypeptide (OATP) 1B1 transport function by lysosomotropic drug chloroquine: implication in OATP-mediated drug-drug interactions. Mol Pharm. 2016;13(3):839–851.
   PubMed Web of Science ®Google Scholar
• Hou LJ, Raju SS, Abdulah MS, et al. Rifampicin antagonizes the effect of choloroquine on chloroquine-resistant Plasmodium berghei in mice. Jpn J Infect Dis. 2004;57(5):198–202.
   PubMed Web of Science ®Google Scholar
• Kjaer K. Effects of an overdose of chloroquine in a pregnant woman. Am J Trop Med Hyg. 1955;4(2):259–262.
   PubMed Web of Science ®Google Scholar
• Graham JD. An overdose of “plaquenil”. Br Med J. 1960;1(5181):1256.
   PubMed Web of Science ®Google Scholar
• Gunja N, Roberts D, McCoubrie D, et al. Survival after massive hydroxychloroquine overdose. Anaesth Intensive Care. 2009;37(1):130–133.
   PubMed Web of Science ®Google Scholar
• Hantson P, Ronveau JL, De Coninck B, et al. Amrinone for refractory cardiogenic shock following chloroquine poisoning. Intensive Care Med. 1991;17(7):430–431.
   PubMed Web of Science ®Google Scholar
• Jordan P, Brookes JG, Nikolic G, et al. Hydroxychloroquine overdose: toxicokinetics and management. J Toxicol Clin Toxicol. 1999;37(7):861–864.
   PubMed Web of Science ®Google Scholar
• Keller T, Schneider A, Lamprecht R, et al. Fatal chloroquine intoxication. Forensic Sci Int. 1998;96(1):21–28.
   PubMed Web of Science ®Google Scholar
• Muhm M, Stimpfl T, Malzer R, et al. Suicidal chloroquine poisoning: clinical course, autopsy findings, and chemical analysis. J Forensic Sci. 1996;41(6):1077–1079.
   PubMed Web of Science ®Google Scholar
• Murphy LR, Maskell KF, Kmiecik KJ, et al. Intravenous lipid emulsion use for severe hydroxychloroquine toxicity. Am J Ther. 2018;25(2):e273–e275.
   PubMed Web of Science ®Google Scholar
• Rajah A. The use of diazepam in chloroquine poisoning. Anaesthesia. 1990;45(11):955–957.
   PubMed Web of Science ®Google Scholar
• Ten Broeke R, Mestrom E, Woo L, et al. Early treatment with intravenous lipid emulsion in a potentially lethal hydroxychloroquine intoxication. Neth J Med. 2016;74:210–214.
   PubMed Web of Science ®Google Scholar
• Ling Ngan Wong A, Tsz Fung Cheung I, Graham CA. Hydroxychloroquine overdose: case report and recommendations for management. Eur J Emerg Med off J Eur Soc Emerg Med. 2008;15:16–18.
   PubMed Web of Science ®Google Scholar
• Yanturali S, Aksay E, Demir OF, et al. Massive hydroxychloroquine overdose. Acta Anaesthesiol Scand. 2004;48(3):379–381.
   PubMed Web of Science ®Google Scholar
• Reddy VG, Sinna S. Chloroquine poisoning: report of two cases. Acta Anaesthesiol Scand. 2000;44(8):1017–1020.
   PubMed Web of Science ®Google Scholar
• Ball DE, Tagwireyi D, Nhachi CFB. Chloroquine poisoning in Zimbabwe: a toxicoepidemiological study. J Appl Toxicol. 2002;22(5):311–315.
   PubMed Web of Science ®Google Scholar
• Marquardt K, Albertson TE. Treatment of hydroxychloroquine overdose. Am J Emerg Med. 2001;19(5):420–424.
   PubMed Web of Science ®Google Scholar
• Isbister GK, Dawson A, Whyte IM. Hydroxychloroquine overdose: a prospective case series. Am J Emerg Med. 2002;20(4):377–378.
   PubMed Web of Science ®Google Scholar
• Clemessy JL, Taboulet P, Hoffman JR, et al. Treatment of acute chloroquine poisoning: a 5-year experience. Crit Care Med. 1996;24(7):1189–1195.
   PubMed Web of Science ®Google Scholar
• de Olano J, Howland MA, Su MK, et al. Toxicokinetics of hydroxychloroquine following a massive overdose. Am J Emerg Med. 2019;37(12):2264.e5–e8.
   Web of Science ®Google Scholar
• Henderson A, Adamson M, Pond SM. Death from inadvertent chloroquine overdose. Med J Aust. 1994;160(4):231.
   PubMed Web of Science ®Google Scholar
• Chansky PB, Werth VP. Accidental hydroxychloroquine overdose resulting in neurotoxic vestibulopathy. BMJ Case Rep. 2017. DOI:10.1136/bcr-2016-218786. Online ahead of print.
   Google Scholar
• Bethlehem C, Jongsma M, Korporaal-Heijman J, et al. Cardiac arrest following chloroquine overdose treated with bicarbonate and lipid emulsion. Neth J Med. 2019;77(5):186–188.
   PubMed Web of Science ®Google Scholar
• Phipps C, Chan K, Teo F, et al. Fatal chloroquine poisoning: a rare cause of sudden cardiac arrest. Ann Acad Med Singap. 2011;40(6):296–297.
   PubMed Web of Science ®Google Scholar
• Stiff G, Robinson D, Cugnoni HL, et al. Massive chloroquine overdose-a survivor. Postgrad Med J. 1991;67(789):678–679.
   PubMed Web of Science ®Google Scholar
• Jaeger A, Sauder P, Kopferschmitt J, et al. Clinical features and management of poisoning due to antimalarial drugs. Med Toxicol Adverse Drug Exp. 1987;2(4):242–273.
   PubMedGoogle Scholar
• Mégarbane B, Bloch V, Hirt D, et al. Blood concentrations are better predictors of chioroquine poisoning severity than plasma concentrations: a prospective study with modeling of the concentration/effect relationships. Clin Toxicol Phila Pa. 2010;48(9):904–915.
   PubMed Web of Science ®Google Scholar
• Zaki SA, Mauskar A, Shanbag P. Toxic psychosis due to chloroquine overdose: a case report. J Vector Borne Dis. 2009;46(1):81–82.
   PubMed Web of Science ®Google Scholar
• Ward WQ, Walter-Ryan WG, Shehi GM. Toxic psychosis: a complication of antimalarial therapy. J Am Acad Dermatol. 1985;12(5 Pt 1):863–865.
   PubMed Web of Science ®Google Scholar
• Wilkinson R, Mahatane J, Wade P, et al. Chloroquine poisoning. BMJ. 1993;307(6902):504.
   PubMed Web of Science ®Google Scholar
• Smith ER, Klein-Schwartz W. Are 1-2 dangerous? Chloroquine and hydroxychloroquine exposure in toddlers. J Emerg Med. 2005;28(4):437–443.
   PubMed Web of Science ®Google Scholar